SunTrust Banks, Inc. Boosts Sarepta Therapeutics Inc (SRPT) Price Target to $31.00

Sarepta Therapeutics Inc (NASDAQ:SRPT) had its price target lifted by stock analysts at SunTrust Banks, Inc. from $30.00 to $31.00 in a report released on Thursday, StockTargetPrices.com reports. SunTrust Banks, Inc.’s price target would suggest a potential downside of 4.73% from the stock’s current price.

SRPT has been the topic of a number of other research reports. Royal Bank of Canada boosted their price target on shares of Sarepta Therapeutics from $98.00 to $106.00 and gave the company an “outperform” rating in a report on Friday, December 16th. Vetr upgraded shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating and set a $34.53 price objective on the stock in a research note on Monday, March 20th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $76.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 16th. Cowen and Company reiterated an “outperform” rating and issued a $62.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, December 21st. Finally, Robert W. Baird reiterated a “buy” rating and issued a $102.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, January 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Sarepta Therapeutics has an average rating of “Buy” and a consensus target price of $56.74.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) traded down 2.1515% during mid-day trading on Thursday, hitting $31.8399. The stock had a trading volume of 682,812 shares. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $63.73. The firm has a 50-day moving average of $30.62 and a 200-day moving average of $35.06. The stock’s market cap is $1.75 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, February 28th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.33) by $0.62. The firm had revenue of $5.42 million for the quarter, compared to analyst estimates of $4.86 million. During the same quarter in the prior year, the firm earned ($1.44) EPS. The firm’s revenue was up 333.6% compared to the same quarter last year. On average, analysts forecast that Sarepta Therapeutics will post ($2.50) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/04/21/sarepta-therapeutics-inc-srpt-price-target-increased-to-31-00-by-analysts-at-suntrust-banks-inc-updated.html.

Several institutional investors have recently added to or reduced their stakes in SRPT. BlackRock Advisors LLC increased its position in Sarepta Therapeutics by 488.2% in the third quarter. BlackRock Advisors LLC now owns 839,928 shares of the biotechnology company’s stock worth $51,580,000 after buying an additional 697,122 shares during the last quarter. Jennison Associates LLC increased its position in Sarepta Therapeutics by 86.6% in the third quarter. Jennison Associates LLC now owns 1,393,788 shares of the biotechnology company’s stock worth $85,593,000 after buying an additional 647,030 shares during the last quarter. Redmile Group LLC acquired a new position in Sarepta Therapeutics during the third quarter worth approximately $39,327,000. Norges Bank acquired a new position in Sarepta Therapeutics during the fourth quarter worth approximately $11,181,000. Finally, BlackRock Group LTD increased its position in Sarepta Therapeutics by 433.6% in the third quarter. BlackRock Group LTD now owns 412,069 shares of the biotechnology company’s stock worth $25,304,000 after buying an additional 334,842 shares during the last quarter. 76.75% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

5 Day Chart for NASDAQ:SRPT

Stock Target Prices

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply